BSH 2021 - 61st British Society for Haematology Annual Scientific Meeting (Virtual Meeting)
Apr 25 - Apr 28, 2021 | LiverpoolUK
LARVOL is not affiliated with 61st British Society for Haematology Annual Scientific Meeting (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 54 abstracts linked to Trials
[VIRTUAL] Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up
[VIRTUAL] Pevonedistat + azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia: a phase 2 randomized study
[VIRTUAL] Addition of parsaclisib (INCB050465), a PI3Kd inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with myelofibrosis
[VIRTUAL] CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel in relapsed/ Refractory multiple myeloma
[VIRTUAL] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/ Refractory multiple myeloma: first results from the CC-220-MM-001 study
[VIRTUAL] Primary analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-hodgkin lymphoma
[VIRTUAL] Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel as first-line therapy in patients with high-risk large B-cell lymphoma
[VIRTUAL] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton’s Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
[VIRTUAL] ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30- positive peripheral T-cell lymphoma: 5-year results
[VIRTUAL] One year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/Refractory mantle cell lymphoma
[VIRTUAL] Pharmacological profile and clinical outcomes of KTE-X19 by prior bruton tyrosine kinase inhibitor exposure or mantle cell lymphoma morphology in patients with relapsed/ refractory mantle cell lymphoma in the ZUMA-2 trial
[VIRTUAL] Efficacy and safety of mogamulizumab by patient blood classification
[VIRTUAL] Recovery of ocular events with longer-term follow-up in the DREAMM-2 study of single- agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
[VIRTUAL] CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/ intolerant to jak inhibitor: update from phase 2 manifest study
[VIRTUAL] A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis